About Heron Therapeutics, Inc.
https://www.herontx.comHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
CEO
Craig Alexander Collard
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-01-13 | Reverse | 1:20 |
| 2007-05-25 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 62
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
RUBRIC CAPITAL MANAGEMENT LP
Shares:29.1M
Value:$43.36M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:10.24M
Value:$15.26M
BLACKROCK, INC.
Shares:9.99M
Value:$14.88M
Summary
Showing Top 3 of 232
About Heron Therapeutics, Inc.
https://www.herontx.comHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $38.21M ▲ | $26.92M ▼ | $-17.5M ▼ | -45.78% ▼ | $-0.1 ▼ | $-13.98M ▼ |
| Q2-2025 | $37.2M ▼ | $28.98M ▲ | $-2.38M ▼ | -6.4% ▼ | $-0.02 ▼ | $-1.03M ▼ |
| Q1-2025 | $38.9M ▼ | $27.29M ▲ | $2.63M ▼ | 6.77% ▼ | $0.02 ▼ | $3.71M ▼ |
| Q4-2024 | $40.78M ▲ | $26.38M ▼ | $3.66M ▲ | 8.98% ▲ | $0.02 ▲ | $8.73M ▲ |
| Q3-2024 | $32.81M | $27.81M | $-4.85M | -14.78% | $-0.03 | $-3.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $55.49M ▲ | $248.95M ▲ | $234.06M ▼ | $14.88M ▲ |
| Q2-2025 | $40.63M ▼ | $232.09M ▼ | $259.35M ▼ | $-27.26M ▲ |
| Q1-2025 | $50.68M ▼ | $235.75M ▲ | $264.2M ▼ | $-28.45M ▲ |
| Q4-2024 | $59.28M ▼ | $233.15M ▲ | $266.8M ▲ | $-33.65M ▲ |
| Q3-2024 | $70.89M | $220.78M | $260.78M | $-40.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.5M ▼ | $1.33M ▲ | $11.86M ▲ | $13.36M ▲ | $26.55M ▲ | $1.33M ▲ |
| Q2-2025 | $-2.38M ▼ | $-10.87M ▼ | $7.33M ▲ | $781K ▲ | $-2.75M ▲ | $-11.08M ▼ |
| Q1-2025 | $2.63M ▼ | $-8.87M ▲ | $2.27M ▼ | $64K ▼ | $-6.53M ▼ | $-8.98M ▲ |
| Q4-2024 | $3.66M ▲ | $-11.78M ▼ | $11.42M ▲ | $423K ▲ | $61K ▼ | $-12.42M ▼ |
| Q3-2024 | $-4.85M | $3.37M | $3.97M | $14K | $7.36M | $2.94M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 C I N V A N T I | $50.00M ▲ | $30.00M ▼ | $20.00M ▼ | $20.00M ▲ |
 S U S T O L | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Z Y N R E L E F | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Craig Alexander Collard
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-01-13 | Reverse | 1:20 |
| 2007-05-25 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 62
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
RUBRIC CAPITAL MANAGEMENT LP
Shares:29.1M
Value:$43.36M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:10.24M
Value:$15.26M
BLACKROCK, INC.
Shares:9.99M
Value:$14.88M
Summary
Showing Top 3 of 232